Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point.
DOI: 10.1001/JAMANEUROL.2014.1120
关键词:
摘要: The chief difference between a primary prevention trial (PPT) and secondary (SPT) in Alzheimer's disease (AD) is related to the targeted participant group. As currently conceptualized, PPT recruits asymptomatic individuals from general population while an SPT only (or preclinical) who are biomarker-positive for AD1. Recent examples of latter include AD kindred Antioquia, Colombia, which subjects E280A mutation carriers with familial history early onset disease, Anti-Amyloid Treatment Asymptomatic Disease (A4) trial, targets adults age 70 years older high brain amyloid levels as determined by PET scan. subject Donohue et al. manuscript2, seeks identify endpoint that SPT.
sci-hub.se 参考文章(9)
M. Colin Ard, Steven D. Edland, Power Calculations for Clinical Trials in Alzheimer's Disease Journal of Alzheimer's Disease. ,vol. 26, pp. 369- 377 ,(2011) , 10.3233/JAD-2011-0062
Jagan A. Pillai, Jeffrey L. Cummings, Clinical Trials in Predementia Stages of Alzheimer Disease Medical Clinics of North America. ,vol. 97, pp. 439- 457 ,(2013) , 10.1016/J.MCNA.2013.01.002
Paul K. Crane, , Adam Carle, Laura E. Gibbons, Philip Insel, R. Scott Mackin, Alden Gross, Richard N. Jones, Shubhabrata Mukherjee, S. McKay Curtis, Danielle Harvey, Michael Weiner, Dan Mungas, Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Brain Imaging and Behavior. ,vol. 6, pp. 502- 516 ,(2012) , 10.1007/S11682-012-9186-Z
Chengjie Xiong, Gerald van Belle, Kewei Chen, Lili Tian, Jingqin Luo, Feng Gao, Yan Yan, Ling Chen, John C. Morris, Paul Crane, Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease. Statistics in Biopharmaceutical Research. ,vol. 5, pp. 54- 66 ,(2013) , 10.1080/19466315.2012.756662
ELLEN GROBER, CHARLES B. HALL, RICHARD B. LIPTON, ALAN B. ZONDERMAN, SUSAN M. RESNICK, CLAUDIA KAWAS, Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. Journal of The International Neuropsychological Society. ,vol. 14, pp. 266- 278 ,(2008) , 10.1017/S1355617708080302
Richard J. Kryscio, Marta S. Mendiondo, Frederick A. Schmitt, William R. Markesbery, Designing a large prevention trial: statistical issues Statistics in Medicine. ,vol. 23, pp. 285- 296 ,(2004) , 10.1002/SIM.1716
Maria C. Carrillo, H. Robert Brashear, Veronika Logovinsky, J. Michael Ryan, Howard H. Feldman, Eric R. Siemers, Susan Abushakra, Dean M. Hartley, Ronald C. Petersen, Ara S. Khachaturian, Reisa A. Sperling, Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers & Dementia. ,vol. 9, pp. 123- ,(2013) , 10.1016/J.JALZ.2012.12.004
Lon S. Schneider, Richard E. Kennedy, Gary R. Cutter, , Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers & Dementia. ,vol. 6, pp. 367- 377 ,(2010) , 10.1016/J.JALZ.2010.07.004
Laurel A Beckett, Danielle J Harvey, Anthony Gamst, Michael Donohue, John Kornak, Hao Zhang, Julie H Kuo, Alzheimer's Disease Neuroimaging Initiative, The Alzheimer’s Disease Neuroimaging Initiative: Annual Change in Biomarkers and Clinical Outcomes Alzheimers & Dementia. ,vol. 6, pp. 257- 264 ,(2010) , 10.1016/J.JALZ.2010.03.002